Activated Charcoal Aloe Carbo Animalis Hamamelis V

證據等級: L5

預測適應症: 0 個

Multi-Ingredient Homeopathic Preparation: TxGNN Evaluation Incomplete — Insufficient Data

One-Sentence Summary

This entry contains a 15-component complex preparation including homeopathic substances (Lachesis Muta Venom, Nux-Vomica, Sepia Officinalis, Sulfur, Lycopodium) alongside botanical astringents and venotropic agents historically associated with anorectal conditions. The TxGNN model could not generate a repurposing prediction because no DrugBank ID was matched and no predicted indications were returned. As a result, no evidence table, clinical trial data, or repurposing score is available for this candidate.

Quick Overview

Item	Content
Original Indication	Not established (no regulatory record in Taiwan or US)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only — but no prediction was generated)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

This candidate is a 15-ingredient combination whose components span four distinct pharmacological categories:

Activated adsorbents — Activated Charcoal, Carbo Animalis
Botanical venotropics / astringents — Hamamelis Virginiana, Horse Chestnut, Krameria Lappacea, Paeonia Officinalis, Aloe
Classical homeopathic dilutions — Lachesis Muta Venom, Lycopodium Clavatum Spore, Sepia Officinalis Juice, Strychnos Nux-Vomica Seed, Sulfur, Nitric Acid, Hydrochloric Acid
Mineral supplement — Tribasic Calcium

The ingredient profile (particularly Hamamelis, Horse Chestnut, Krameria, Paeonia, Nux-Vomica, Nitric Acid, and Sepia) is consistent with multi-component anorectal / hemorrhoid preparations common in European homeopathic markets. However, TxGNN operates on single-entity DrugBank nodes; this multi-ingredient entry has no drugbank_id, so the knowledge graph cannot assign a node identity and no graph traversal prediction is possible.

Mechanistic analysis is therefore not feasible at this stage.

Safety Considerations

Please refer to each individual component’s package insert and regulatory monograph for safety information. Notable concerns at the ingredient level include:

Strychnos Nux-Vomica Seed — contains strychnine alkaloids; narrow therapeutic index in non-homeopathic doses
Lachesis Muta Venom — snake-derived; hemotoxic at pharmacological concentrations
Nitric Acid / Hydrochloric Acid — corrosive agents requiring strict dilution verification

No formal DDI data was retrieved for this combination formulation.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline cannot evaluate a multi-ingredient entry without a resolved DrugBank node. Additionally, this preparation contains homeopathic components whose efficacy is not recognised by regulatory bodies in conventional evidence frameworks, making repurposing analysis methodologically inappropriate without decomposition into individual active ingredients.

To proceed, the following is needed:

Ingredient decomposition: Evaluate each pharmacologically active component (Hamamelis, Horse Chestnut, Krameria, Activated Charcoal) as a separate TxGNN candidate with its own DrugBank ID
Exclude homeopathic dilutions: Components used at homeopathic potencies (e.g., Lachesis, Sepia, Sulfur, Lycopodium, Nux-Vomica) should be flagged as out-of-scope for TxGNN, which requires conventional pharmacological concentrations
Confirm product identity: Verify whether this formulation corresponds to a known branded product (e.g., a rectal suppository or cream marketed in Europe) to locate any existing regulatory record
Safety document retrieval: Obtain the originating manufacturer’s SmPC or product insert to establish contraindications and warnings before any clinical assessment
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.